Because the molecular clock in the melatonin-producing cells of the pineal gland plays a key role in modulating circadian behavior [110], since circadian clocks are considered potential therapeutic targets to attenuate onsets and progressions of neurodegenerative diseases like AD [94], and considering melatonin therapy as an advantageous modality in terms of therapeutics [111], using melatonin-based approaches to mitigate circadian rhythm disruptions in aging and neurodegenerative diseases would certainly delay the onset or abate the development of AD pathogenesis. This evidence concerns the gene CLOCK and Alzheimer disease.